Blarcamesine
drugOn this page
Also known as AnavexBlarcamesina
Summary
Blarcamesine (CHEMBL4297224) is a phase-3 clinical-stage small molecule targeting SIGMAR1.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 1 (SIGMAR1)
- Chemistry: 281.4 Da · C19H23NO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297224 |
| Name | Blarcamesine |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 9882189 |
| Molecular formula | C19H23NO |
| Molecular weight | 281.4 |
| InChIKey | BOTHKNZTGGXFEQ-UHFFFAOYSA-N |
SMILES: CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3
IUPAC name: 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
Also known as: Anavex, Blarcamesina, Blarcamesine, BLARCAMESINE
Parent form; salt/anhydrous children: CHEMBL4594269
Patent coverage: 196 distinct patent families (489 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| SIGMAR1 | sigma non-opioid intracellular receptor 1 | Agonist | 6.07 | 2.6% | Q99720 |
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Sigma non-opioid intracellular receptor 1.
Bioactivity
ChEMBL activities: 11 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| SIGMAR1 | 8.2 | Ki | 6.3 | nM | CHEMBL_ACT_25506944 |
| SIGMAR1 | 6.07 | IC50 | 860 | nM | CHEMBL_ACT_22850774 |
| SIGMAR1 | 6.07 | IC50 | 860 | nM | CHEMBL_ACT_24977774 |
| CHRM1 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_22850848 |
| CHRM2 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_22850850 |
| CHRM3 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_22850851 |
| CHRM4 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_22850852 |
| CHRM1 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_24977781 |
| CHRM2 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_24977782 |
| CHRM3 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_24977783 |
| CHRM4 | 5.48 | IC50 | 3300 | nM | CHEMBL_ACT_24977784 |
Target pathways
Aggregated over 1 target gene(s): SIGMAR1.
Top Reactome pathways
5 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Disease | 1 | SIGMAR1 |
| Infectious disease | 1 | SIGMAR1 |
| Potential therapeutics for SARS | 1 | SIGMAR1 |
| SARS-CoV Infections | 1 | SIGMAR1 |
| Viral Infection Pathways | 1 | SIGMAR1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| lipid transport | 1 |
| nervous system development | 1 |
| regulation of neuron apoptotic process | 1 |
| protein homotrimerization | 1 |
| response to alcohol | 1 |
| regulation of postsynapse assembly | 1 |
| G protein-coupled opioid receptor signaling pathway | 1 |
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
143 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| METHAMPHETAMINE | ChEMBL + PubChem | Phase 4 (approved) | SIGMAR1 |
| AMANTADINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BETAXOLOL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BREXPIPRAZOLE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BROMHEXINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BUFLOMEDIL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BUSPIRONE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| BUTENAFINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CARBETAPENTANE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CHLOROQUINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CINACALCET | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CITALOPRAM | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| CLOZAPINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| COCAINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DEXCHLORPHENIRAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DEXFENFLURAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DEXTROMETHORPHAN | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DICYCLOMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DIHYDROERGOTAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DIMENHYDRINATE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DIPHENIDOL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DOBUTAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DONEPEZIL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| DOXEPIN | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| FENTANYL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| FLUOXETINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| FLUVOXAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| HYDROXYCHLOROQUINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| ILOPERIDONE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| KETANSERIN | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| LABETALOL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| LASMIDITAN | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| LEVAMFETAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| LEVOBUNOLOL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| LOPERAMIDE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| MAZINDOL | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| MEPAZINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| METHYSERGIDE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| MIFEPRISTONE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| NAFTIFINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| OXYBUTYNIN | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| PAROXETINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| PENTAZOCINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| PERHEXILINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| PHENTOLAMINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| PIPAMAZINE | ChEMBL | Phase 4 (approved) | SIGMAR1 |
| PITOLISANT | ChEMBL | Phase 4 (approved) | SIGMAR1 |
Related Atlas pages
- Genes: SIGMAR1
- Drugs: Methamphetamine, Amantadine, Amiodarone, Amitriptyline, Astemizole, Azelastine, Benztropine, Betaxolol, Brexpiprazole, Bromhexine, Buflomedil, Buspirone, Butenafine, Carbetapentane, Chloroquine, Chlorpromazine, Cinacalcet, Cinnarizine, Cisapride, Citalopram, Clemastine, Clomipramine, Clozapine, Cocaine, Dexchlorpheniramine, Dexfenfluramine, Dextromethorphan, Dicyclomine, Dihydroergotamine, Dimenhydrinate, Diphenidol, Dobutamine, Donepezil, Doxepin, Econazole, Fentanyl, Fluoxetine, Fluphenazine, Fluvoxamine, Haloperidol, Hydroxychloroquine, Iloperidone, Ketanserin, Labetalol, Lasmiditan, Levamfetamine, Levobunolol, Loperamide, Mazindol, Mepazine, Methysergide, Mifepristone, Naftifine, Oxybutynin, Paroxetine, Pentazocine, Perhexiline, Phentolamine, Pipamazine, Pitolisant